Anti-KIR3DL1 antibodies

Patent metadata

Field	Value
Publication number	US-11117964-B2
Application number	US-201816484451-A
Country	US
Kind code	B2
Filing date	Feb 26, 2018
Priority date	Feb 9, 2017
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.

First claim

The invention claimed is:

1. An antibody or antigen binding fragment thereof comprising:
(a) a heavy chain CDR1 sequence comprising SEQ ID NO:23, a heavy chain CDR2 sequence comprising SEQ ID NO:24, a heavy chain CDR3 sequence comprising SEQ ID NO:25, a light chain CDR1 sequence comprising SEQ ID NO:20, a light chain CDR2 sequence comprising SEQ ID NO:21, and a light chain CDR3 sequence comprising SEQ ID NO:22;
(b) a heavy chain CDR1 sequence comprising SEQ ID NO:29, a heavy chain CDR2 sequence comprising SEQ ID NO:30, a heavy chain CDR3 sequence comprising SEQ ID NO:31, a light chain CDR1 sequence comprising SEQ ID NO:26, a light chain CDR2 sequence comprising SEQ ID NO:27 and a light chain CDR3 sequence comprising SEQ ID NO:28;
(c) a heavy chain CDR1 sequence comprising SEQ ID NO:35, a heavy chain CDR2 sequence comprising SEQ ID NO:36, a heavy chain CDR3 sequence comprising SEQ ID NO:37, a light chain CDR1 sequence comprising SEQ ID NO: 32, a light chain CDR2 sequence comprising SEQ ID NO:33 and a light chain CDR3 sequence comprising SEQ ID NO:34;
(d) a heavy chain CDR1 sequence comprising SEQ ID NO:41, a heavy chain CDR2 sequence comprising SEQ ID NO:42, a heavy chain CDR3 sequence comprising SEQ ID NO:43; a light chain CDR1 sequence comprising SEQ ID NO:38, a light chain CDR2 sequence comprising SEQ ID NO:39 and a light chain CDR3 sequence comprising SEQ ID NO:40;
(e) a heavy chain CDR1 sequence comprising SEQ ID NO:47, a heavy chain CDR2 sequence comprising SEQ ID NO:48, a heavy chain CDR3 sequence comprising SEQ ID NO:49, a light chain CDR1 sequence comprising SEQ ID NO:44, a light chain CDR2 sequence comprising SEQ ID NO:45 and a light chain CDR3 sequence comprising SEQ ID NO:46;
(f) a heavy chain CDR1 sequence comprising SEQ ID NO:53, a heavy chain CDR2 sequence comprising SEQ ID NO:54, a heavy chain CDR3 sequence comprising SEQ ID NO:55, a light chain CDR1 sequence comprising SEQ ID NO:50, a light chain CDR2 sequence comprising SEQ ID NO:51 and a light chain CDR3 sequence comprising SEQ ID NO:52; or
(g) a heavy chain CDR1 sequence comprising SEQ ID NO:59, a heavy chain CDR2 sequence comprising SEQ ID NO:60, a heavy chain CDR3 sequence comprising SEQ ID NO:61, a light chain CDR1 sequence comprising SEQ ID NO:56, a light chain CDR2 sequence comprising SEQ ID NO:57 and a light chain CDR3 sequence comprising SEQ ID NO:58.

2. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises:
(a) a heavy chain variable region having a sequence selected from SEQ ID NOs: 7, 9, 11, 13, 15, 17, and 19; and
(b) a light chain variable region having a sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, and 18.

3. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is monoclonal, humanized or chimeric.

4. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment
blocks binding of human KIR3DL1 to HLA-Bw4;
activates natural killer cells;
binds to one or more alleles of KIR3DL1 selected from the group consisting of: *001, *002,*007, *015, *020, and *033; and/or
binds to an allele of KIR3DL1 with a K D of about 1 nM to 50 nM.

5. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is conjugated to a payload selected from the group consisting of isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA or any combination thereof.

6. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment binds to an epitope of KIR3DL1 protein, wherein KIR3DL1 protein comprises an extracellular domain, wherein the epitope is a sequence present within the extracellular domain of KIR3DL1 protein, and wherein the extracellular domain of KIR3DL1 comprises a sequence selected from the group consisting of SEQ ID NOs: 1-5.

7. A nucleic acid molecule encoding the antibody or antigen binding fragment of claim 1 .

8. A recombinant vector or a host cell comprising or the nucleic acid molecule of claim 7 .

9. The host cell of claim 8 , wherein the host cell is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell a mammalian cell, an E. coli cell, a P. pastoris cell, a Sf9 cell, a COS cell, a HEK293 cell, a CHO cell, and a mammalian lymphocyte.

10. A pharmaceutical composition comprising:
(a) the antibody or antigen binding fragment of claim 1 ; and
(b) a pharmaceutically acceptable carrier.

11. A method of manufacturing the pharmaceutical composition of claim 10 by combining the antibody or antigen binding fragment, with the pharmaceutically acceptable carrier and formulating for administration to a subject.

12. A kit comprising the antibody or antigen binding fragment claim 1 and instructions for use.

13. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising the antibody or antigen binding fragment of claim 1 .

14. The method of claim 13 , wherein the subject has been diagnosed with or is at risk for developing cancer.

15. The method of claim 13 , wherein the cancer is a leukemia, a solid tumor, acute myeloid leukemia (AML) or neuroblastoma.

16. The method of claim 13 , wherein the subject expresses an allele of KIR3DL1.

17. The method of claim 16 , wherein the allele of KIR3DL1 is selected from the group consisting of: *001, *016, *026, *027, *043, *052, *059, *060, *061, *064, *065, *067, *075, *002, *015, *008, *009, *020, *006, *017, *018, *022, *023, *024N, *025, *028, *029, *030, *031, *034, *035, *038, *042, *051, *054, *057, *062, *074, *076, *077, *005, *041, *044, *053, *007, *032, *068, *013, *010, *011, *012, *014, *045, *046, *047, *048, *049N, *050, *055, *058, *073, *004, *019, *021, *036, *037, *039, *040, *056, *063, *033 and *072.

18. The method of claim 16 , wherein the allele of KIR3DL1 has been detected in a sample obtained from the subject.

19. The method of claim 16 , wherein the subject has, is or will receive at least one additional therapy for the treatment of cancer, and optionally wherein the additional therapy is an anti-GD2 immunotherapy.

20. The method of claim 13 , wherein the composition comprising the antibody or antigen binding fragment is administered orally, intranasally, parenterally, intravenously, intramuscularly, intraperitoneally, subcutaneously, rectally, intrathecally, intratumorally or topically.

Assignees

• Memorial Sloan Kettering Cancer Center
• Eureka Therapeutics Inc

Inventors

• Hsu Katharine
• Cheung Nai-Kong V
• Yan Su
• Xu Yiyang
• Xiang Jingyi
• Liu Cheng

Classifications

• A61P35/02

  specific for leukemia · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K14/70503

  Immunoglobulin superfamily · CPC title